Guggenheim Maintains Buy on Tango Therapeutics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Charles Zhu maintains a Buy rating on Tango Therapeutics (NASDAQ:TNGX) but lowers the price target from $16 to $14.
May 24, 2024 | 4:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Guggenheim analyst Charles Zhu maintains a Buy rating on Tango Therapeutics but lowers the price target from $16 to $14.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100